SGLT-2i/GLP-1 RA/DPP-4i combination treatment for cardio-renal-metabolic protection in T2DM patients

The role of combining a sodium glucose cotransporter-2 inhibitor and either a glucagon-like peptide-1receptor agonist or dipeptidyl peptidase-4 enzyme inhibitor in managing patients with type 2 diabetes mellitus, cardiovascular disease and chronic kidney disease were discussed by experts during the EMPIRE Summit 2023.